Literature DB >> 25376620

[Bullous pemphigoid: a new look at a well-known disease].

G Balakirski1, H F Merk, M Megahed.   

Abstract

BACKGROUND: Bullous pemphigoid is an autoimmune blistering disease that is associated with appearance of subepidermal blisters. IgG antibodies against components of the epithelial basement membrane (BP 180 and 230 antigens) can be typically found in serum of patients. Direct immunofluorescence reveals usually a linear deposition of IgG and/or C3 along the basement membrane, but other immunoglobulins may also be present. CASE
PRESENTATION: Our patient had no detectable formation of tense blisters of his skin; instead, the clinical picture was rather compatible with a prurigo simplex subacuta or a pruritic variant of atopic dermatitis. He also had a markedly elevated total serum IgE level. The diagnosis was confirmed by detection of circulating IgG against BP 180 in patient's serum in ELISA and detection of linear IgG deposits along the basement membrane zone of epidermis in the direct immunofluorescence.
CONCLUSION: Atypical clinical presentations of bullous pemphigoid without blister formation are possible. Recent studies show that an increased total IgE level in serum of patients may occur frequently. The aim of this report is to provide the reader with a brief insight in the new findings in pathogenesis and therapy of bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25376620     DOI: 10.1007/s00105-014-3538-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  34 in total

1.  DEMONSTRATION OF SKIN ANTIBODIES IN SERA OF PEMPHIGUS VULGARIS PATIENTS BY INDIRECT IMMUNOFLUORESCENT STAINING.

Authors:  E H BEUTNER; R E JORDON
Journal:  Proc Soc Exp Biol Med       Date:  1964-11

2.  Successful treatment of bullous pemphigoid with omalizumab.

Authors:  Vanessa A London; Gene H Kim; Janet A Fairley; David T Woodley
Journal:  Arch Dermatol       Date:  2012-11

3.  Basement zone antibodies in bullous pemphigoid.

Authors:  R E Jordon; E H Beutner; E Witebsky; G Blumental; W L Hale; W F Lever
Journal:  JAMA       Date:  1967-05-29       Impact factor: 56.272

4.  [Immunopathologic changes in 115 patients with bullous pemphigoid].

Authors:  W Kippes; E Schmidt; A Roth; B Rzany; E B Bröcker; D Zillikens
Journal:  Hautarzt       Date:  1999-12       Impact factor: 0.751

5.  IgE and its related phenomena in bullous pemphigoid.

Authors:  H Soh; H Hosokawa; Y Asada
Journal:  Br J Dermatol       Date:  1993-04       Impact factor: 9.302

6.  Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients.

Authors:  A Gual; P Iranzo; J M Mascaró
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-04-13       Impact factor: 6.166

7.  [Cyclosporin in the treatment of bullous pemphigoid: preliminary study].

Authors:  H Barthélémy; J Thivolet; F Cambazard; A Bendelac; G Mauduit; F Granier; A Frappaz
Journal:  Ann Dermatol Venereol       Date:  1986       Impact factor: 0.777

8.  Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.

Authors:  Arzu Didem Yalcin; Gizem Esra Genc; Betul Celik; Saadet Gumuslu
Journal:  Clin Lab       Date:  2014       Impact factor: 1.138

9.  Azathioprine in treatment of bullous pemphigoid.

Authors:  M W Greaves; J L Burton; J Marks; R P Dawber
Journal:  Br Med J       Date:  1971-01-16

10.  Omalizumab therapy for bullous pemphigoid.

Authors:  Kenneth K Yu; Ashley B Crew; Kelly A N Messingham; Janet A Fairley; David T Woodley
Journal:  J Am Acad Dermatol       Date:  2014-06-20       Impact factor: 15.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.